ArticleBMC infectious diseases2026
Real-world efficacy of comprehensive measures against mother-to-child transmission of HBV in south-eastern Jiangsu, China.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundReducing mother-to-child transmission (MTCT) is the crucial step towards eliminating hepatitis B virus (HBV) infection. The aim of this study is to evaluate the efficiency of intervention programme to MTCT of HBV in China and establish a foundation for future clinical practice and policy formulation.
methodsA retrospective cross-sectional study was conducted and data was collected from the iPMTCT Programme. From January 2021 and June 2024, the puerpera of hepatitis B surface antigen (HBsAg) infection and infants born to HBsAg-positive mothers in Nantong city were enrolled in this study. In puerpera, the screening rate, HBsAg prevalence rate and antiviral treatment rate were analyzed. In infants, administration of combined immunoprophylaxis, MTCT rate and relative factors of MTCT were analyzed respectively.
resultsFrom January 2021 and June 2024, 99,391 pregnant women received HBV screening and 2797 of them were tested positive for HBsAg. The overall HBsAg prevalence of pregnant women steadily dropped from 3.03% to 2.62%. The overwhelming majority of newborns born to HBsAg-positive mothers were immunized with HepB and HBIG timely after birth and got post-vaccination serologic testing (PVST)after completing three-dose vaccine. MTCT rate of at-risk neonates also exhibited a declining trend following the implementation of interventions (from 0.55% to 0.29%). Logistic analysis indicated that antiviral therapy of pregnant women with high-viral load (HBV DNA ≥ 2 × 10^5) served as an independent protective factor against preventing MTCT (OR = 0.091; 95% CI: 0.01 ~ 0.821, P < 0.05).
conclusionsThe implementation of comprehensive measures against MTCT of HBV achieves remarkable progress and laid the root for achieving the HBV elimination goals in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.